3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
11
Genitourinary
9
Gynecologic
6
Tumor-Agnostic
3
Gastrointestinal
3
Thoracic
2
Sarcoma
2
Other hematologic neoplasm
2
CNS
2
Plasma cell
1
Other solid neoplasm
1
Lymphoid
1
Endocrine
1
Conditions
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
262
Lenalidomide
157
daratumumab
135
Bortezomib
113
pomalidomide
89
Calcium Dobesilate
86
Cyclophosphamide
84
carfilzomib
76
Specimen Handling
46
isatuximab
44
fludarabine
43
Biopsy
43
belantamab mafodotin
41
Magnetic Resonance Spectroscopy
38
dexamethasone acetate
34
dexamethasone 21-phosphate
34
auricularum
33
Melphalan
32
talquetamab
29
ixazomib
27
iberdomide
27
fludarabine phosphate
24
selinexor
22
elotuzumab
21
Whole-Body Irradiation
17
X-Rays
15
venetoclax
14
Mycophenolic Acid
13
tocilizumab
12
Stem Cell Transplantation
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
talazoparib
×
Plasma cell
×
1 year
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled